ertified medical oncologist, is a member
of the Board of Directors of Unibioscreen, Eurogentec and DNA therapeutics,
and formerly was a Director of Newron, Entomed, Neurotech, Novexel and
CropDesign. Dr. Thomas is currently a Senior Advisor at Bryan Garnier, a
Paris-based investment bank, and is responsible for corporate finance
activities for pharmaceutical and biotechnology companies. Dr. Thomas has
been a Venture Partner at Atlas Venture (London, UK), and a General Manager
at Bioserve Ltd (Cambridge, UK), a consultancy for the life science arena.
He was previously Vice President Licensing, Medical Affairs and
Pharmacogenomics at Genset (Paris, France), Vice President, Clinical
Development at Ipsen (Paris, France) and Assistant Professor of Medical
Oncology at Institut Gustave Roussy (Paris, France).
Four of the current directors, Dr. James Barrett, Mr. John Friedman,
Ms. Gail Schulze and Dr. Julius Vida, will not be standing for re-election.
The Board of Directors will be reduced from ten to eight members.
About YM BioSciences
YM BioSciences Inc. is an oncology company that identifies, develops
and commercializes differentiated products for patients worldwide. The
Company has two late-stage products: nimotuzumab, a humanized monoclonal
antibody that targets the epidermal growth factor receptor (EGFR) and is
approved in several countries for treatment of various types of head and
neck cancer; and AeroLEF(TM), a proprietary, inhaled-delivery composition
of free and liposome-encapsulated fentanyl in development for the treatment
of moderate to severe pain, including cancer pain.
This press release may contain forward-looking statements, which
reflect the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
Page: 1 2 3 Related biology technology :1
|SOURCE YM BioSciences Inc.|
Copyright©2007 PR Newswire.
All rights reserved
. Perscitus Biosciences secures $250K Commerce loan2
. Wisconsin biosciences rise to the challenge3
. Quintessence Biosciences advances cancer drug4
. Quintessence Biosciences names new president5
. Caden Biosciences may signal critical mass6
. Wisconsin start up Primorigen Biosciences corrals out-of-state investment7
. WARF signs licensing pact with BD Biosciences8
. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces9
. State awards QRG Biosciences development grant10
. EMD Biosciences partners with European biotech company11
. Quintessence Biosciences forms cancer therapeutic advisory board